Literature DB >> 30798382

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy.

Michael A Feuerstein1, Leah Goldstein2, Brieyona Reaves2, Arony Sun2, Michael Goltzman2, Bradley A Morganstern2, Ahmad Shabsigh2, Dean F Bajorin2, Jonathan E Rosenberg2, S Machele Donat2, Harry W Herr2, Vincent P Laudone2, Thomas M Atkinson3, Yuelin Li3, Guido Dalbagni2, Bruce Rapkin4, Bernard H Bochner2.   

Abstract

PURPOSE: To evaluate patient-reported outcomes (PROs) for bladder cancer patients undergoing neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) using longitudinal data and propensity-matched scoring analyses.
METHODS: 155 patients with muscle-invasive bladder cancer scheduled for RC completed the European Organization for Research and Treatment of Cancer questionnaires, EORTC QLQ-C30, EORTC QLQ-BLM30, Fear of Recurrence Scale, Mental Health Inventory and Satisfaction with Life Scale within 4 weeks of surgery. A propensity-matched analysis was performed comparing pre-surgery PROs among 101 patients who completed NAC versus 54 patients who did not receive NAC. We also compared PROs pre- and post-chemotherapy for 16 patients who had data available for both time points.
RESULTS: In propensity-matched analysis, NAC-treated patients reported better emotional and sexual function, mental health, urinary function and fewer financial concerns compared to those that did not receive NAC. Longitudinal analysis showed increases in fatigue, nausea and appetite loss following chemotherapy.
CONCLUSION: Propensity-matched analysis did not demonstrate a negative effect of NAC on PRO. Several positive associations of NAC were found in the propensity-matched analysis, possibly due to other confounding differences between the two groups or actual clinical benefit. Longitudinal analysis of a small number of patients found small to modest detrimental effects from NAC similar to toxicities previously reported. Our preliminary findings, along with known survival and toxicity data, should be considered in decision-making for NAC.

Entities:  

Keywords:  Bladder cancer; Health-related quality of life; Patient-centered research; Patient-reported outcomes

Mesh:

Year:  2019        PMID: 30798382      PMCID: PMC6707898          DOI: 10.1007/s00345-019-02692-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  19 in total

1.  The Satisfaction With Life Scale.

Authors:  E Diener; R A Emmons; R J Larsen; S Griffin
Journal:  J Pers Assess       Date:  1985-02

2.  Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Authors:  Amir Sherif; Erkki Rintala; Oddvar Mestad; Jonas Nilsson; Lars Holmberg; Sten Nilsson; Per-Uno Malmström
Journal:  Scand J Urol Nephrol       Date:  2002

3.  Mastectomy patients and the fear of cancer recurrence.

Authors:  L L Northouse
Journal:  Cancer Nurs       Date:  1981-06       Impact factor: 2.592

4.  The missing voice of patients in drug-safety reporting.

Authors:  Ethan Basch
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

5.  Interpreting the significance of changes in health-related quality-of-life scores.

Authors:  D Osoba; G Rodrigues; J Myles; B Zee; J Pater
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Authors:  Atreya Dash; Joseph A Pettus; Harry W Herr; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Paul Russo; Mary G Boyle; Matthew I Milowsky; Dean F Bajorin
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

7.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.

Authors:  Michael P Porter; Matthew C Kerrigan; Bonnie M K Donato; Scott D Ramsey
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group.

Authors:  P U Malmström; E Rintala; R Wahlqvist; P Hellström; S Hellsten; E Hannisdal
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

10.  Performance of a five-item mental health screening test.

Authors:  D M Berwick; J M Murphy; P A Goldman; J E Ware; A J Barsky; M C Weinstein
Journal:  Med Care       Date:  1991-02       Impact factor: 2.983

View more
  1 in total

1.  Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting.

Authors:  Mona Kamal; Neema Navai; Kelly K Bree; Loretta A Williams; Charles S Cleeland; Shu-En Shen; Xin Shelley Wang
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.